Skip to content
RKWD
ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|
Rockwood Research
…

DMAC

DiaMedica Therapeutics Inc.

Pharmaceutical Preparations · SIC 2834CIK 1401040Held by 1 tracked managerEDGAR filings ↗10-K/10-Q ↗

SHARE:XLINKEDINEMAIL
Revenue FY2025
—
Net Income FY2025
$(33.0M)
EPS (Basic, as reported)
$-0.70
Net Margin FY2025
—
ROE FY2025
-58.4%
Total Equity
$56.0M
Shares Out
54M
Business description

DiaMedica Therapeutics Inc. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2017–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions
i
default rows · click any row to chart it
Fiscal yearFY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue—1———————
Research & development(3)(5)(8)(8)(9)(8)(13)(19)(25)
General & administrative(1)(3)(4)(4)(5)(6)(8)(8)(10)
Total operating expenses(5)(7)(12)(13)(14)(14)(21)(27)(34)
Operating income(5)(7)(12)(13)(14)(14)(21)(27)(34)
Interest & investment income——————222
Other income (expense), net011000222
Pre-tax income(4)(6)(11)(12)(14)(14)(19)(24)(33)
Income tax expense—00000000
Net income(4)(6)(11)(12)(14)(14)(19)(24)(33)
EPS — basic————($0.65)($0.52)($0.60)($0.60)($0.70)
Shares outstanding — basic (M)————2126334047

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.